Literature DB >> 11709012

Cycloplegic refractions in healthy children aged 1 through 48 months.

D L Mayer1, R M Hansen, B D Moore, S Kim, A B Fulton.   

Abstract

OBJECTIVES: To provide a description of refractive errors in healthy, term-born children, aged 1 through 48 months, and to test the hypotheses that spherical equivalent becomes significantly less hyperopic and less variable with increasing age.
METHODS: Following a prospective, cross-sectional design, cycloplegic retinoscopy was used to measure the refractive error in both eyes of 514 healthy, term-born children in 12 age groups. Three hundred were aged 12 months or younger. Spherical equivalent and cylindrical power and axis were analyzed as a function of age. Prediction limits for spherical equivalent were calculated.
RESULTS: Spherical equivalents of right and left eyes did not differ at any age. Hyperopia declined significantly with increasing age. The variability in spherical equivalent also decreased significantly with age. Cylindrical error of 1 diopter or more was found in 25% of the children; the proportion with astigmatism was highest in infancy and then waned. Myopia and anisometropia were rare, occurring in 3% and 1% of the sample, respectively.
CONCLUSIONS: Significant declines in hyperopia and variability of spherical equivalent appear to be features of emmetropization. The normal prediction limits provide guidelines against which data from individual patients can be compared.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709012     DOI: 10.1001/archopht.119.11.1625

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  94 in total

1.  Are there more exotropes than esotropes in Hong Kong?

Authors:  S R Lambert
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

2.  Multifocal ERG in subjects with a history of retinopathy of prematurity.

Authors:  Anne B Fulton; Ronald M Hansen; Anne Moskowitz; Amber M Barnaby
Journal:  Doc Ophthalmol       Date:  2006-02-25       Impact factor: 2.379

3.  Human infants' accommodation responses to dynamic stimuli.

Authors:  Grazyna M Tondel; T Rowan Candy
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-02       Impact factor: 4.799

4.  Foveal fine structure in retinopathy of prematurity: an adaptive optics Fourier domain optical coherence tomography study.

Authors:  Daniel X Hammer; Nicusor V Iftimia; R Daniel Ferguson; Chad E Bigelow; Teoman E Ustun; Amber M Barnaby; Anne B Fulton
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01-25       Impact factor: 4.799

5.  The evolution of refractive status in Chinese infants during the first year of life and its affected factors.

Authors:  Shu-Juan Yu; Guo-Hua Liu; Yi Liu; Jing Huang; Ming-Lei Han; Bo-Jun Zhao; Zhong-Tao Gai
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

6.  The stability of steady state accommodation in human infants.

Authors:  T Rowan Candy; Shrikant R Bharadwaj
Journal:  J Vis       Date:  2007-08-17       Impact factor: 2.240

7.  Onset and progression of with-the-rule astigmatism in children with infantile nystagmus syndrome.

Authors:  Jingyun Wang; Lauren M Wyatt; Joost Felius; David R Stager; David R Stager; Eileen E Birch; Harold E Bedell
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-17       Impact factor: 4.799

8.  Cues for the control of ocular accommodation and vergence during postnatal human development.

Authors:  Shrikant R Bharadwaj; T Rowan Candy
Journal:  J Vis       Date:  2008-12-22       Impact factor: 2.240

9.  Is emmetropia the natural endpoint for human refractive development? An analysis of population-based data from the refractive error study in children (RESC).

Authors:  Ian G Morgan; Kathryn A Rose; Leon B Ellwein
Journal:  Acta Ophthalmol       Date:  2010-12       Impact factor: 3.761

10.  Accommodative and vergence responses to conflicting blur and disparity stimuli during development.

Authors:  Shrikant R Bharadwaj; T Rowan Candy
Journal:  J Vis       Date:  2009-10-05       Impact factor: 2.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.